HIV Epidemiology and Drug Resistance

Dear Colleagues,

At the end of 2020, it was estimated that 37.7 million people were living with HIV-1. The availability of antiretroviral therapy (ART) enabled access to therapy for 27.5 million of these people, worldwide. This global use of ART has been accompanied by the emergence of HIV drug resistance, which can compromise the effectiveness of ART. To this end, the WHO has recommended that countries routinely perform HIV drug-resistance surveys. The impacts of drug-resistance mutations on different anti-HIV drugs are not identical, and genetic barriers, doze and dozing schedule may all impact therapy outcome. Adherence and immunological factors may also affect treatment success. Here, we would like to address global and regional HIV epidemiology and to assess the magnitude and type of transmitted, pretreatment and acquired drug-resistance mutations.

Research studies can be focused on the epidemiology of HIV-1, screening, mutation analysis and evaluation of drug resistance, plus estimation of HIV-1 reservoirs and resistance mutations. Studies aiming at establishing technologies including those for the development and evaluation of diagnostic and recency assays, viral load tests and sequencing technologies for estimating HIV resistance, are also within the scope of this Special Issue.

Dr. Orna Mor
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.